LSTA vs. RNXT, FBRX, ITRM, APM, ONCT, TXMD, UBX, BFRG, ACST, and BIOR
Should you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include RenovoRx (RNXT), Forte Biosciences (FBRX), Iterum Therapeutics (ITRM), Aptorum Group (APM), Oncternal Therapeutics (ONCT), TherapeuticsMD (TXMD), Unity Biotechnology (UBX), Bullfrog AI (BFRG), Acasti Pharma (ACST), and Biora Therapeutics (BIOR). These companies are all part of the "pharmaceutical preparations" industry.
RenovoRx (NASDAQ:RNXT) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.
RenovoRx's return on equity of -39.90% beat Lisata Therapeutics' return on equity.
In the previous week, Lisata Therapeutics had 2 more articles in the media than RenovoRx. MarketBeat recorded 9 mentions for Lisata Therapeutics and 7 mentions for RenovoRx. Lisata Therapeutics' average media sentiment score of 1.11 beat RenovoRx's score of 0.93 indicating that RenovoRx is being referred to more favorably in the media.
RenovoRx is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
RenovoRx and Lisata Therapeutics both received 6 outperform votes by MarketBeat users. However, 85.71% of users gave Lisata Therapeutics an outperform vote while only 37.50% of users gave RenovoRx an outperform vote.
RenovoRx presently has a consensus target price of $8.50, suggesting a potential upside of 494.41%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 426.32%. Given Lisata Therapeutics' higher probable upside, equities analysts clearly believe RenovoRx is more favorable than Lisata Therapeutics.
RenovoRx has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
3.1% of RenovoRx shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 7.1% of RenovoRx shares are held by insiders. Comparatively, 21.6% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Lisata Therapeutics beats RenovoRx on 8 of the 13 factors compared between the two stocks.
Get Lisata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lisata Therapeutics Competitors List
Related Companies and Tools
